SAN DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (OTCBB: ADMP), announced today that its wholly owned subsidiary, Adamis Labs has now secured distribution contracts and initial stocking orders from the three major wholesalers of prescription drugs in the U.S. These three wholesalers distribute approximately 90 percent of U.S. drugs made by manufacturers. With the recent shipments of product, Adamis’ pre-filled epinephrine syringe (Epinephrine Injection USP 1:1000 [0.3mg]) will be available to most pharmacies in the U.S. Since many of the major health insurance companies have classified Adamis’ pre-filled epinephrine syringe in Tier 1, (their lowest copay) Adamis can offer allergic patients the opportunity to purchase a low cost and potentially lifesaving medicine. Dr. Dennis J Carlo, President and CEO of Adamis stated, “We are just laying the foundation to enable Adamis to capture a significant portion of the $200 million epinephrine market. We plan to hire a salesforce over the next few months to help raise awareness and accelerate sales growth of our epi syringe.”
